Amarin Corp ADR (AMRN) Stock Price, Quote & News

Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty p...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 353 0 166 99020

Website: www.amarincorp.com

Address:

One Central Plaza, 5th Floor 36 Dame Street, Dublin 2, Ireland

Painman Aug. 4 at 9:49 PM

$AMRN .. what is everybody’s guess if they get a buyout? $1 billion? So that’s a 3X from here. I’ve been stuck in this turd now forever.

1 · Reply

SanDiegoLiving Aug. 4 at 8:14 PM

$AMRN 🧵 Post 1/6 – 📊 11 IPE Presentations: Amarin Makes Its Boldest ESC Showing Yet 📍 ESC Congress | Madrid | Aug 29–Sept 2 📡 5 Scientific Sessions | 🧠 11 Total Presentations on Icosapent Ethyl (IPE) Amarin may have handed off European commercialization to Recordati, but it remains the scientific driver behind IPE. ESC 2025 features the deepest IPE lineup to date—spanning real-world evidence, trial data, implementation, and prevention. 🔹 CALLINICUS Registry: post-ACS reinfarction risk 🔹 REDUCE-IT CKM: systemic CVRM patient impact 🔹 Libby-chaired expert panel: ASCVD integration 🔹 Amarin-supported EU symposium: real-world tools 🔹 🦇 Bhatt anchors with prevention strategy 💼 11 presentations. Full visibility. Strategic intent. ⬇️ First up: CALLINICUS shows what’s still hiding behind statin therapy.

1 · Reply

SanDiegoLiving Aug. 4 at 8:14 PM

$AMRN 🧵 Post 2/6 – 📊 CALLINICUS Registry | Early Post-ACS Risk 📌 “IPE-eligible patients following ACS are at increased risk of reinfarction” 🎙️ Dr. Loukianos Rallidis 🇬🇷 | Attikon University Hospital 🕒 ESC Congress 2025 | Madrid 🧪 1,254 ACS patients screened 4–12 weeks post-discharge 📈 25.6% met IPE eligibility (TG 135–499 mg/dL, on statins) 💥 MI rate in eligible group: 5.9% vs 3.1% non-eligible 📊 Adjusted HR: 2.0 for reinfarction within 12 months Most patients had LDL-C controlled and were already on high-intensity statins. Despite this, residual TG-driven risk persisted—unmasked in early follow-up. This registry validates IPE as a targeted option for intervention during the vulnerable post-ACS period. Amarin continues delivering real-world relevance while Recordati scales commercial rollout in Europe. ⬇️ Next: Dr. Miller presents REDUCE-IT CKM data in systemic, high-burden patients.

0 · Reply

SanDiegoLiving Aug. 4 at 8:14 PM

$AMRN 🧵 Post 3/6 – 🧬 REDUCE-IT CKM | Systemic Risk Uncovered 📌 “IPE reduces CVD risk in cardiovascular-kidney-metabolic syndrome” 🎙️ Dr. Michael Miller 🇺🇸 | Philadelphia VA 🕒 ESC Congress 2025 | Madrid 🫀 CKM = ASCVD + Type 2 diabetes + CKD 🔥 High-risk, inflamed, treatment-resistant population 📉 IPE reduced CV events in this REDUCE-IT subgroup ⚙️ Benefit persisted despite overlapping comorbidities This session expands IPE’s value beyond lipid-lowering—positioning it as a tool in multi-system CVRM, not just cholesterol management. CKM patients often fall between clinical silos; IPE closes that gap with inflammation-targeted effect. Amarin continues delivering frontline data post-commercial handoff. While Recordati drives execution in Europe, Amarin sharpens clinical precision. ⬇️ Next: Dr. Libby leads a KOL panel on risk-based ASCVD integration.

0 · Reply

SanDiegoLiving Aug. 4 at 8:14 PM

$AMRN 🧵 Post 4/6 – 🧠 Libby Panel | ASCVD Risk Integration 📌 “Integrating Icosapent Ethyl Into Long-Term ASCVD Risk Reduction” 🗓️ Aug 29 | 15:30–16:00 | ESC Congress | Madrid 🇪🇸 🎙️ Chair: Dr. Peter Libby 🇺🇸 🗣️ Speakers: Stroes 🇳🇱 | Steg 🇫🇷 | Taub 🇺🇸 🎯 Key Topics: 📉 Triglyceride-driven residual risk in statin-treated patients 🧪 REDUCE-IT outcomes applied to real-world populations ⚙️ Practical treatment pathways, access, and adherence Libby leads a globally respected group in shaping the future of ASCVD prevention. Focus is on how to deploy IPE—phenotype targeting, treatment escalation, and post-LDL control strategies. While Recordati manages commercialization, Amarin continues guiding clinicians with credible, high-impact programming. This panel delivers strategic alignment from data to action. ⬇️ Next: Amarin’s EU symposium focuses on real-world case models and physician execution.

0 · Reply

SanDiegoLiving Aug. 4 at 8:14 PM

$AMRN 🧵 Post 5/6 – Amarin EU Symposium | Evidence ➝ Action 📌 “Addressing Residual Cardiovascular Risk: From Evidence to Experience” 🎙️ Steg 🇫🇷 | Zamorano 🇪🇸 | Marcucci 🇮🇹 🕒 Aug 29 | 15:15–16:00 | Hall 10 💡 What’s delivered: 📚 Trial overview (REDUCE-IT, EVAPORATE) 🇪🇸 Spanish real-world IPE experience 🛠️ Case selection + practical implementation This prescriber-facing session ties together data, access, and treatment models. Even post-commercial handoff, Amarin leads the education layer. Recordati handles formulary and volume. Amarin equips the clinicians. ⬇️ Final act: 🦇 Dr. Bhatt returns with prevention strategy that anchors the entire IPE program

0 · Reply

SanDiegoLiving Aug. 4 at 8:14 PM

$AMRN 🧵 Post 6/6 – Bhatt on ASCVD Prevention | Strategic Anchor 📌 “New Frontiers in ASCVD Risk Reduction: Integrating Icosapent Ethyl” 🎙️ Dr. Deepak L. Bhatt | 🇺🇸 Mount Sinai 🧠 Session highlights: 📊 Phenotype-driven risk modeling 🕒 Timing across primary and secondary prevention ⚖️ Bridging trial criteria and real-world complexity Bhatt shaped REDUCE-IT and continues defining how IPE applies to actual patients—not ideal trial profiles. Frameworks are built for use, not theory. As commercialization scales with Recordati, Bhatt solidifies the science and closes ESC’s IPE arc with strategic clarity. IPE started with evidence. It now expands with integration. 🧩 ESC 2025 showcases science, structure, and global alignment.

0 · Reply

Ilikebeinggreen Aug. 4 at 7:45 PM

$AMRN Curious how many others on here worked on Wall St. I worked at a bulge bracket IB before I retired.

0 · Reply

Ilikebeinggreen Aug. 4 at 6:22 PM

$AMRN This stock should be a MEME stock. It's guaranteed money for retail that is patient and let the process work.

2 · Reply

Ilikebeinggreen Aug. 4 at 6:21 PM

$AMRN The CEO basically told us they are working on a deal. I'll keep buying. Foolish if you don't. Hard to predict what price they'll get but it will be much higher than current levels. Guaranteed money and people sitting on the sidelines. We should all be piling in and forcing a bigger premium.

3 · Reply

Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 7:00 AM EDT - 5 days ago

Amarin Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 7:30 AM EDT - 12 days ago

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

Jun 24, 2025, 7:05 AM EDT - 5 weeks ago

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

May 7, 2025, 11:01 AM EDT - 3 months ago

Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 4:15 PM EDT - 3 months ago

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 28, 2025, 4:15 PM EDT - 3 months ago

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Apr 14, 2025, 10:02 AM EDT - 4 months ago

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

H THO ALMS CCO ECX HZO NUTX

Apr 9, 2025, 7:30 AM EDT - 4 months ago

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Apr 7, 2025, 7:30 AM EDT - 4 months ago

Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

Mar 19, 2025, 12:45 PM EDT - 4 months ago

Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

Mar 19, 2025, 7:30 AM EDT - 4 months ago

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Mar 12, 2025, 10:30 AM EDT - 5 months ago

Amarin Corporation plc (AMRN) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:00 AM EST - 5 months ago

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

Feb 19, 2025, 8:30 AM EST - 5 months ago

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

Dec 16, 2024, 7:00 AM EST - 8 months ago

Amarin Receives National Reimbursement for VAZKEPA® in Italy

Dec 13, 2024, 9:00 AM EST - 8 months ago

Amarin Appoints Peter Fishman Chief Financial Officer

Nov 19, 2024, 7:52 AM EST - 9 months ago

Top 3 Health Care Stocks You'll Regret Missing In Q4

SLN TERN

Oct 30, 2024, 8:50 PM EDT - 9 months ago

Amarin Corporation plc (AMRN) Q3 2024 Earnings Call Transcript

Sep 9, 2024, 7:30 AM EDT - 11 months ago

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting

Aug 22, 2024, 8:30 AM EDT - 1 year ago

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Jul 31, 2024, 12:28 PM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 17, 2024, 4:15 PM EDT - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

Jul 17, 2024, 8:00 AM EDT - 1 year ago

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

Jul 8, 2024, 7:30 AM EDT - 1 year ago

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

Jun 7, 2024, 7:16 PM EDT - 1 year ago

LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok

Jun 4, 2024, 7:30 AM EDT - 1 year ago

Amarin Board of Directors Announces CEO Transition

May 28, 2024, 8:15 AM EDT - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

May 6, 2024, 8:00 AM EDT - 1 year ago

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 1, 2024, 10:43 AM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q1 2024 Earnings Call Transcript

May 1, 2024, 7:00 AM EDT - 1 year ago

Amarin Reports First Quarter 2024 Business Update and Financial Results

Apr 24, 2024, 2:00 PM EDT - 1 year ago

Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Apr 22, 2024, 8:00 AM EDT - 1 year ago

Amarin Announces Results of Annual General Meeting of Shareholders

Apr 15, 2024, 8:00 AM EDT - 1 year ago

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

Apr 8, 2024, 8:00 AM EDT - 1 year ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Apr 6, 2024, 3:30 PM EDT - 1 year ago

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Mar 25, 2024, 8:00 AM EDT - 1 year ago

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Feb 29, 2024, 10:18 AM EST - 1 year ago

Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 7:00 AM EST - 1 year ago

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 15, 2024, 8:00 AM EST - 1 year ago

Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

Jan 22, 2024, 7:30 AM EST - 1 year ago

Amarin Chairman & CEO Issue Letter to Shareholders

Jan 15, 2024, 3:06 AM EST - 1 year ago

Amarin: Sarissa Is Giving Me Hope Again

Jan 10, 2024, 6:40 PM EST - 1 year ago

Amarin Corporation plc (AMRN) CEO Pat Holt presents at 42nd Annual J.P. Morgan Healthcare Conference (Transcript)

Jan 10, 2024, 7:00 AM EST - 1 year ago

Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

Dec 11, 2023, 8:00 AM EST - 1 year ago

Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 4, 2023, 4:23 PM EST - 1 year ago

Sarissa Capital Believes Amarin Stock Is Meaningfully Undervalued and Has Increased Its Ownership

Nov 12, 2023, 9:00 AM EST - 1 year ago

New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline

Nov 1, 2023, 10:40 AM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q3 2023 Earnings Call Transcript

Painman Aug. 4 at 9:49 PM

$AMRN .. what is everybody’s guess if they get a buyout? $1 billion? So that’s a 3X from here. I’ve been stuck in this turd now forever.

1 · Reply

SanDiegoLiving Aug. 4 at 8:14 PM

1 · Reply

SanDiegoLiving Aug. 4 at 8:14 PM

0 · Reply

SanDiegoLiving Aug. 4 at 8:14 PM

0 · Reply

SanDiegoLiving Aug. 4 at 8:14 PM

0 · Reply

SanDiegoLiving Aug. 4 at 8:14 PM

0 · Reply

SanDiegoLiving Aug. 4 at 8:14 PM

0 · Reply

Ilikebeinggreen Aug. 4 at 7:45 PM

$AMRN Curious how many others on here worked on Wall St. I worked at a bulge bracket IB before I retired.

0 · Reply

Ilikebeinggreen Aug. 4 at 6:22 PM

$AMRN This stock should be a MEME stock. It's guaranteed money for retail that is patient and let the process work.

2 · Reply

Ilikebeinggreen Aug. 4 at 6:21 PM

3 · Reply

Noche Aug. 4 at 4:06 PM

$AMRN who’s responsible to get Vazkepa approved in France and Germany? Can Recordati speed things up?

1 · Reply

declanaidan Aug. 4 at 12:53 PM

$AMRN A very interesting collaboration just announced this morning in Massachusetts Mass General Brigham hospital system, biggest in state, is joining with CVS to operate 37 MinuteClinics to offer primary care staffed by nurse practitioners / physicians assistants. They will have prescription writing capabilities and we can assume more Vascepa scripts will now be covered by CVS pharmacies. It's a model, MinuteClinics, we can expect to see more of across the country. P.S. Dr Bhatt was at the Brigham while overseeing the Reduce It study, before recently moving to Mt Sinai.

3 · Reply

CaptBeer Aug. 4 at 12:48 PM

$AMRN The Bad Guys are Cholesterol Crystals: https://www.linkedin.com/feed/update/urn:li:activity:7357369143399985153?commentUrn=urn%3Ali%3Acomment%3A%28activity%3A7357369143399985153%2C7358116343977578498%29&dashCommentUrn=urn%3Ali%3Afsd_comment%3A%287358116343977578498%2Curn%3Ali%3Aactivity%3A7357369143399985153%29

0 · Reply

CaptBeer Aug. 4 at 12:37 PM

$AMRN IPE is at ESCcongress 2025 in Madrid, Spain: https://www.linkedin.com/posts/amelia-carro-hevia-90534468_ipe-at-esc-congress-ugcPost-7357862731657502720-akuZ?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAdDmycBzT_CwLIulyFqANe8SLMF4KH2Odo

0 · Reply

Ilikebeinggreen Aug. 4 at 12:20 PM

$AMRN Acquisition process clearly in progress. Stupid not to buy more.

1 · Reply

BobGood Aug. 3 at 1:39 PM

$AMRN Wow .. What a misleading statement... Vascepa & Repatha manufactured by HLS, Canada ??

2 · Reply

DoMoreCharity Aug. 3 at 1:30 PM

$AMRN Hawkesbury pharmacist receives accolades for paper on promising drug to treat COVID-19 symptoms Jan 12, 2021 https://thereview.ca/2021/01/12/hawkesbury-pharmacist-receives-accolades-for-paper-on-promising-drug-to-treat-covid-19-symptoms/

0 · Reply

DoMoreCharity Aug. 3 at 1:25 PM

$AMRN “Brady said the two best medications currently available for heart conditions are Vascepa and Repatha, manufactured by HLS Therapeutics.“ https://thereview.ca/2025/08/01/hawkesbury-pharmacist-takes-cardiac-care-to-the-community/

1 · Reply

CaptBeer Aug. 3 at 12:36 PM

$AMRN Let me try that link again regarding EPA for inflammatory risk reduction. https://www.linkedin.com/feed/update/urn:li:activity:7357369143399985153?commentUrn=urn%3Ali%3Acomment%3A%28activity%3A7357369143399985153%2C7357390963100581888%29&replyUrn=urn%3Ali%3Acomment%3A%28activity%3A7357369143399985153%2C7357565281667305473%29&dashCommentUrn=urn%3Ali%3Afsd_comment%3A%287357390963100581888%2Curn%3Ali%3Aactivity%3A7357369143399985153%29&dashReplyUrn=urn%3Ali%3Afsd_comment%3A%287357565281667305473%2Curn%3Ali%3Aactivity%3A7357369143399985153%29

1 · Reply

CaptBeer Aug. 3 at 12:18 AM

$AMRN https://www.linkedin.com/feed/update/urn:li:activity:7357369143399985153?commentUrn=urn%3Ali%3Acomment%3A%28activity%3A7357369143399985153%2C7357390963100581888%29&replyUrn=urn%3Ali%3Acomment%3A%28activity%3A7357369143399985153%2C7357565281667305473%29&dashCommentUrn=urn%3Ali%3Afsd_comment%3A%287357390963100581888%2Curn%3Ali%3Aactivity%3A7357369143399985153%29&dashReplyUrn=urn%3Ali%3Afsd_comment%3A%287357565281667305473%2Curn%3Ali%3Aactivity%3A7357369143399985153%29

0 · Reply

declanaidan Aug. 2 at 4:46 PM

$AMRN Maybe Amarin should consider re incorporating in USA, from Ireland? The impetus for Ireland, like many pharma and tech companies, was taxes. That no longer holds and in fact significant tax advantage now to be a US company, and especially if we can pull some manfacturing to US? The Amarin Dublin "HQ" is basically a leased office with almost no employees actually working there. Also untangles some of the cumbersome Irish/UK corporate regulations.

4 · Reply

AA694629 Aug. 2 at 4:33 PM

$AMRN do we still have 275 employees?

1 · Reply

Market Cap	313.92M
Revenue (ttm)	228.61M
Net Income (ttm)	-82.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-35.95%
Debt to Equity Ratio	0.00

Volume	67,700
Avg Vol	120,532
Day's Range	N/A - N/A
Shares Out	20.71M
Stochastic %K	68%
Beta	0.84
Analysts	Buy
Price Target	$11.00